Prescription drug · NDA
Arikayce (Amikacin) NDC 71558-590
Amikacin 590 mg/8.4mL · Suspension · Respiratory (Inhalation) · Insmed Incorporated
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71558-590-28 | 71558059028 | 28 VIAL in 1 CARTON (71558-590-28) / 8.4 mL in 1 VIALMarketed from Oct 12, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Arikayce
- Generic name (nonproprietary)
- amikacin
- Active ingredients
- Amikacin — 590 mg/8.4mL
- Dosage form
- Suspension
- Route
- Respiratory (Inhalation)
- Labeler
- Insmed IncorporatedNDC labeler code 71558
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 207356
- Marketing start
- Listing expires
- Other FDA classes
- Aminoglycosides (Chemical structure)
- Identifiers
- Product ID 71558-590_8b162ccf-7672-4cd4-9448-7d104971418fSPL ID 8b162ccf-7672-4cd4-9448-7d104971418fSPL set ID 499ab990-2b21-474f-aaba-d86388965f40RxCUI 2059184, 2059189UNII 84319SGC3C
- Pharmacologic class
- Aminoglycoside Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N471558059028followed by a unit qualifier and the quantityPackage 71558-0590-28. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options . This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achi…
Excerpt only. Read the full label for complete information.
About NDC 71558-590
- What is NDC 71558-590?
- 71558-590 is the product NDC for Arikayce (amikacin), Amikacin 590 mg/8.4mL suspension, listed with the FDA by Insmed Incorporated. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Arikayce (Amikacin).
- What is the active ingredient?
- Amikacin.
- Who is the labeler?
- Insmed Incorporated, NDC labeler code 71558. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Arikayce?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.